Literature DB >> 16409234

Case report: Avoidance of palpable corporal fibrosis due to priapism with upregulators of nitric oxide.

Jacob Rajfer1, John L Gore, Jeffrey Kaufman, Nestor Gonzalez-Cadavid.   

Abstract

INTRODUCTION: Recent evidence suggests that blocking inducible nitric oxide (NO) synthase in the penis may exacerbate fibrotic processes and that application of medications known to increase NO in tissues may prevent fibrosis. AIM: To report the use of an antifibrotic regimen consisting of medications known to upregulate NO production in two patients with refractory priapism.
METHODS: Two patients presented with priapism of greater than 48-hour duration. After corporal aspiration/irrigation and shunting procedures failed, both were prescribed a daily antifibrotic regimen comprising the phosphodiesterase inhibitors pentoxifylline and sildenafil, and the NO precursor, L-arginine.
RESULTS: At 1 year, both patients were found to have supple corpora without evidence of corporal fibrosis.
CONCLUSIONS: An antifibrotic regimen consisting of upregulators of NO production may ameliorate the corporal fibrosis associated with recalcitrant priapism.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16409234     DOI: 10.1111/j.1743-6109.2005.00090.x

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  11 in total

1.  The effect of pentoxifylline on penile cavernosal tissues in ischemic priapism-induced rat model.

Authors:  Fikret Erdemir; Fatih Firat; Fatma Markoc; Dogan Atilgan; Bekir Suha Parlaktas; Yunus Emre Kuyucu; Yusuf Gencten
Journal:  Int Urol Nephrol       Date:  2014-07-16       Impact factor: 2.370

Review 2.  Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy.

Authors:  Nestor F Gonzalez-Cadavid; Jacob Rajfer
Journal:  Nat Rev Urol       Date:  2010-03-09       Impact factor: 14.432

3.  Pentoxifylline treatment and penile calcifications in men with Peyronie's disease.

Authors:  James F Smith; Alan W Shindel; Yun-Ching Huang; Raul I Clavijo; Lawrence Flechner; Benjamin N Breyer; Michael L Eisenberg; Tom F Lue
Journal:  Asian J Androl       Date:  2010-11-22       Impact factor: 3.285

4.  Treatment with a combination of ginger, L-citrulline, muira puama and Paullinia cupana can reverse the progression of corporal smooth muscle loss, fibrosis and veno-occlusive dysfunction in the aging rat.

Authors:  Monica G Ferrini; Su M Hlaing; Andre Chan; Jorge N Artaza
Journal:  Andrology (Los Angel)       Date:  2015-05-25

5.  Fibrosis and loss of smooth muscle in the corpora cavernosa precede corporal veno-occlusive dysfunction (CVOD) induced by experimental cavernosal nerve damage in the rat.

Authors:  Monica G Ferrini; Istvan Kovanecz; Sandra Sanchez; Chiome Umeh; Jacob Rajfer; Nestor F Gonzalez-Cadavid
Journal:  J Sex Med       Date:  2008-12-02       Impact factor: 3.802

Review 6.  Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease.

Authors:  Elisa Zuccarello; Erica Acquarone; Elisa Calcagno; Elentina K Argyrousi; Shi-Xian Deng; Donald W Landry; Ottavio Arancio; Jole Fiorito
Journal:  Biochem Pharmacol       Date:  2020-01-21       Impact factor: 5.858

Review 7.  Priapism: new concepts in the pathophysiology and new treatment strategies.

Authors:  Trinity J Bivalacqua; Arthur L Burnett
Journal:  Curr Urol Rep       Date:  2006-11       Impact factor: 2.862

Review 8.  Molecular Mechanisms and Current Pharmacotherapy of Peyronie's Disease: A Review.

Authors:  Fuxun Zhang; Feng Qin; Jiuhong Yuan
Journal:  Front Pharmacol       Date:  2021-05-20       Impact factor: 5.810

9.  The aging penis: what is it trying to tell us?

Authors:  Jacob Rajfer
Journal:  Transl Androl Urol       Date:  2012-03

10.  Partial Priapism Treated with Pentoxifylline.

Authors:  Meghan A Cooper; Rafael E Carrion; Christopher Yang
Journal:  Int Braz J Urol       Date:  2015 Jul-Aug       Impact factor: 1.541

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.